ulipristal 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
steroidal compounds acting on progesterone receptors 4166 126784-99-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • CDB-2914
  • ulipristal acetate
  • ella
  • EllaOne
  • esmya
  • ulipristal
Ulipristal acetate is a selective progesterone receptor modulator with antagonistic and partial agonistic effects (a progesterone agonist/antagonist) at the progesterone receptor. It binds the human progesterone receptor and prevents progesterone from occupying its receptor. The likely primary mechanism of action of ulipristal acetate for emergency contraception is inhibition or delay of ovulation.
  • Molecular weight: 475.63
  • Formula: C30H37NO4
  • CLOGP: 4.51
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 0
  • TPSA: 63.68
  • ALOGS: -5.14
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O
5 mg O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 56 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.855 Moderate 0.76
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.977 Moderate 0.76
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 44.978 10^-6 cm/s Moderate 0.76
dh-clint Dog hepatocyte intrinsic clearance 29.580 uL/min/10^6 cells Moderate 0.76
dppb Dog plasma protein binding (% unbound) 0.400 % Moderate 0.76
fcs-ppb Fetal calf serum protein binding (% unbound) 1.420 % Moderate 0.76
herg hERG pIC50 4.780 pIC50 Moderate 0.76
hh-clint Human hepatocyte intrinsic clearance 42.364 uL/min/10^6 cells Moderate 0.76
hlm-clint Human liver microsomal intrinsic clearance 277.971 uL/min/mg protein Moderate 0.76
hppb Human plasma protein binding (% unbound) 0.600 % Moderate 0.76
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,NTRK2,PDK1,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 46
kinase-selectivity-class AXL,EIF2AK3,GRK2,MAP2K6,STK33 5
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.959 Moderate 0.76
mh-clint Mouse hepatocyte intrinsic clearance 148.594 Moderate 0.76
mppb Mouse plasma protein binding (% unbound) 0.610 Moderate 0.76
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 12.162 Moderate 0.76
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 1.510 % Moderate 0.76
rh-clint Rat hepatocyte intrinsic clearance 204.644 uL/min/10^6 cells Moderate 0.76
rh-fuinc Rat hepatocyte fraction unbound in incubation 6.990 % Moderate 0.76
rppb Rat plasma protein binding (% unbound) 0.690 % Moderate 0.76
solubility-dd Solubility at pH 7.4 in DMSO 6.339 uM Moderate 0.76

Approvals:

DateAgencyCompanyOrphan
May 15, 2009 EMA
Aug. 13, 2010 FDA LAB HRA PHARMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Unintended pregnancy 256.89 44.30 45 630 7592 90620180
Abortion spontaneous 100.39 44.30 30 645 54026 90573746
Vaginal haemorrhage 74.09 44.30 21 654 31250 90596522

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Unintended pregnancy 239.65 46.27 38 568 4770 110583923
Abortion spontaneous 102.93 46.27 26 580 34256 110554437
Vaginal haemorrhage 65.28 46.27 17 589 25057 110563636
Uterine haemorrhage 46.46 46.27 9 597 3485 110585208

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G03AD02 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Emergency contraceptives
ATC G03XB02 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
Progesterone receptor modulators
MeSH PA D000080066 Contraceptive Agents, Hormonal
MeSH PA D003270 Contraceptive Agents
MeSH PA D003271 Contraceptive Agents, Female
MeSH PA D012102 Reproductive Control Agents
FDA MoA N0000191262 Selective Progesterone Receptor Modulators
FDA EPC N0000191263 Progesterone Agonist/Antagonist
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:49323 contraceptive drug
CHEBI has role CHEBI:59826 progestin
CHEBI has role CHEBI:71027 progesterone receptor modulator

Related Drugs by ATC class:

G03AD Emergency contraceptives 1 drug
levonorgestrel
G03XB Progesterone receptor modulators 1 drug
mifepristone

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Uterine leiomyoma indication 95315005 DOID:13223
Postcoital contraception indication 268463003
Pregnancy, function contraindication 289908002
Breastfeeding (mother) contraindication 413712001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.7 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
30MG ELLA LAB HRA PHARMA N022474 Aug. 13, 2010 RX TABLET ORAL 10159681 April 13, 2030 A METHOD FOR CONTRACEPTION COMPRISING THE STEP OF ORAL ADMINISTRATION A DOSAGE OF 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
30MG ELLA LAB HRA PHARMA N022474 Aug. 13, 2010 RX TABLET ORAL 10772897 April 13, 2030 A METHOD FOR CONTRACEPTION, THE METHOD COMPRISING ADMINISTERING A TABLET COMPRISING 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
30MG ELLA LAB HRA PHARMA N022474 Aug. 13, 2010 RX TABLET ORAL 9283233 April 13, 2030 METHOD FOR CONTRACEPTION TO A WOMAN COMPRISING ADMINISTERING TO THE WOMAN 30MG OF ULIPRISTAL ACETATE MORE THAN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
30MG ELLA LAB HRA PHARMA N022474 Aug. 13, 2010 RX TABLET ORAL 8426392 June 12, 2030 ELLA IS A PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD
30MG ELLA LAB HRA PHARMA N022474 Aug. 13, 2010 RX TABLET ORAL 8962603 June 12, 2030 METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHT HAVING A BMI OF 25 TO 29.99

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Progesterone receptor Nuclear hormone receptor ANTAGONIST IC50 9.70 IUPHAR IUPHAR

External reference:

IDSource
4030133 VUID
N0000181720 NUI
D09567 KEGG_DRUG
159811-51-5 SECONDARY_CAS_RN
4030133 VANDF
4030140 VANDF
CHEBI:177631 CHEBI
2S0 PDB_CHEM_ID
CHEMBL2103846 ChEMBL_ID
CHEMBL260538 ChEMBL_ID
C094854 MESH_SUPPLEMENTAL_RECORD_UI
C555622 MESH_SUPPLEMENTAL_RECORD_UI
DB08867 DRUGBANK_ID
6J5J15Q2X8 UNII
1005920 RXNORM
175839 MMSL
26777 MMSL
d07495 MMSL
013245 NDDF
013246 NDDF
703249005 SNOMEDCT_US
703250005 SNOMEDCT_US
703737005 SNOMEDCT_US
C0300205 UMLSCUI
8367 INN_ID
13559281 PUBCHEM_CID
7460 IUPHAR_LIGAND_ID
6J5J15Q2X8 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ella HUMAN PRESCRIPTION DRUG LABEL 1 50090-2835 TABLET 30 mg ORAL NDA 28 sections
Ella HUMAN PRESCRIPTION DRUG LABEL 1 50090-5422 TABLET 30 mg ORAL NDA 28 sections
Ella HUMAN PRESCRIPTION DRUG LABEL 1 53002-1630 TABLET 30 mg ORAL NDA 28 sections
Ella HUMAN PRESCRIPTION DRUG LABEL 1 53002-2630 TABLET 30 mg ORAL NDA 28 sections
Ella HUMAN PRESCRIPTION DRUG LABEL 1 67296-1466 TABLET 30 mg ORAL NDA 28 sections
Ella HUMAN PRESCRIPTION DRUG LABEL 1 73302-456 TABLET 30 mg ORAL NDA 28 sections